A Phase 2 Study of BA3011 Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on a PD-1/L-1 Inhibitor

Brief description of study

The purpose of the study is designed to evaluate the efficacy and safety of BA3011 alone and in combination with nivolumab in patients with AXL-expressing tumor membrane percent score (TmPS = 50), metastatic non-small cell lung cancer (NSCLC) who have measurable disease. We want to assess for the anti-tumor activity and clinical activity of BA3011 alone and in combination with nivolumab. The study drug BA3011 is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.


Clinical Study Identifier: s21-00034
ClinicalTrials.gov Identifier: NCT04681131
Principal Investigator: Elaine Shum.
Other Investigators: Danny Perlaza, Samantha VanMaanen, Elka R Travis, Jessica Wang, Sally Lau, Joshua K Sabari, Marissa Rybstein, David Mendoza, Melissa L Martinez, Vamsidhar Velcheti, Jeffrey G Schneider, Avital Benson, James Newman, Natalia Cherkassky.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.